The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy

A. Fournier; J. D. Lalau; Arturo Lopez; Paul R. Marantz; Hans Henrik Parving; Edmund J. Lewis; Raymond P. Bain

doi:10.1056/NEJM199403313301314

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy

A. Fournier, J. D. Lalau, Arturo Lopez, Paul R. Marantz, Hans Henrik Parving, Edmund J. Lewis, Raymond P. Bain

Epidemiology & Population Health

Research output: Contribution to journal › Letter › peer-review

13 Scopus citations

Abstract

To the Editor: Lewis et al. (Nov. 11 issue)¹ report that captopril was beneficial in patients with diabetic nephropathy. We have several questions. Since base-line urinary protein excretion was significantly lower in the captopril group, is it possible that the less severe nephropathy in this group accounted for its slower progression? Does the recommendation that angiotensin-converting-enzyme inhibitors be given to patients with diabetic nephropathy mean that these agents should be given in preference to diuretics and beta-adrenergic antagonists? The latter two types of drugs may have more side effects, but they are the only drugs that have been proved effective.

Original language	English (US)
Pages (from-to)	937-938
Number of pages	2
Journal	New England Journal of Medicine
Volume	330
Issue number	13
DOIs	https://doi.org/10.1056/NEJM199403313301314
State	Published - Mar 31 1994

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1056/NEJM199403313301314

Cite this

@article{2d3a8d20be224ef68dbe12ea9e52c847,

title = "The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy",

abstract = "To the Editor: Lewis et al. (Nov. 11 issue)1 report that captopril was beneficial in patients with diabetic nephropathy. We have several questions. Since base-line urinary protein excretion was significantly lower in the captopril group, is it possible that the less severe nephropathy in this group accounted for its slower progression? Does the recommendation that angiotensin-converting-enzyme inhibitors be given to patients with diabetic nephropathy mean that these agents should be given in preference to diuretics and beta-adrenergic antagonists? The latter two types of drugs may have more side effects, but they are the only drugs that have been proved effective.",

author = "A. Fournier and Lalau, {J. D.} and Arturo Lopez and Marantz, {Paul R.} and Parving, {Hans Henrik} and Lewis, {Edmund J.} and Bain, {Raymond P.}",

year = "1994",

month = mar,

day = "31",

doi = "10.1056/NEJM199403313301314",

language = "English (US)",

volume = "330",

pages = "937--938",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "13",

}

TY - JOUR

T1 - The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy

AU - Fournier, A.

AU - Lalau, J. D.

AU - Lopez, Arturo

AU - Marantz, Paul R.

AU - Parving, Hans Henrik

AU - Lewis, Edmund J.

AU - Bain, Raymond P.

PY - 1994/3/31

Y1 - 1994/3/31

N2 - To the Editor: Lewis et al. (Nov. 11 issue)1 report that captopril was beneficial in patients with diabetic nephropathy. We have several questions. Since base-line urinary protein excretion was significantly lower in the captopril group, is it possible that the less severe nephropathy in this group accounted for its slower progression? Does the recommendation that angiotensin-converting-enzyme inhibitors be given to patients with diabetic nephropathy mean that these agents should be given in preference to diuretics and beta-adrenergic antagonists? The latter two types of drugs may have more side effects, but they are the only drugs that have been proved effective.

AB - To the Editor: Lewis et al. (Nov. 11 issue)1 report that captopril was beneficial in patients with diabetic nephropathy. We have several questions. Since base-line urinary protein excretion was significantly lower in the captopril group, is it possible that the less severe nephropathy in this group accounted for its slower progression? Does the recommendation that angiotensin-converting-enzyme inhibitors be given to patients with diabetic nephropathy mean that these agents should be given in preference to diuretics and beta-adrenergic antagonists? The latter two types of drugs may have more side effects, but they are the only drugs that have been proved effective.

UR - http://www.scopus.com/inward/record.url?scp=0028268330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028268330&partnerID=8YFLogxK

U2 - 10.1056/NEJM199403313301314

DO - 10.1056/NEJM199403313301314

M3 - Letter

C2 - 8114873

AN - SCOPUS:0028268330

SN - 0028-4793

VL - 330

SP - 937

EP - 938

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 13

ER -

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this